Analysis of anthrax and plague biowarfare vaccine interactions with human monocyte-derived dendritic cells

Journal of Immunology

Volumn 175, Issue 11, 2005, Pages 7235-7243

  Skowera, Anna ^a   De Jong, Esther C ^b   Schuitemaker, Joost H N ^b   Allen, Jennifer S ^a   Wessely, Simon C ^c   Griffiths, Gareth ^d   Kapsenberg, Martien ^b   Peakman, Mark ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; CD83 ANTIGEN; CD86 ANTIGEN; HLA DR ANTIGEN; IMMUNOLOGICAL ADJUVANT; PERTUSSIS VACCINE; PLAGUE VACCINE;

ANTHRAX; ARTICLE; BIOLOGICAL WARFARE; CELL GROWTH; CELL INTERACTION; CELL MATURATION; CELL STIMULATION; CELL SURFACE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; EFFECTOR CELL; HOST; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOSTIMULATION; IMMUNOTHERAPY; MONOCYTE; PLAGUE; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

EID: 28244457406     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.11.7235     Document Type: Article

References (30)

1. O'Toole, T., and T. V. Inglesby. 2000. Facing the biological weapons threat. Lancet 356: 1128-1129.
2. Rotz, L. D., A. S. Khan, S. R. Lillibridge, S. M. Ostroff, and J. M. Hughes. 2002. Public health assessment of potential biological terrorism agents. Emerg. Infect. Dis. 8: 225-230.
3. Gruchalla, R. S., and J. Jones. 2003. Combating high-priority biological agents: what to do with drug-allergic patients and those for whom vaccination is contraindicated? J. Allergy Clin. Immunol. 112: 675-682.
4. Goodman, L. 2004. Taking the sting out of the anthrax vaccine. J. Clin. Invest. 114: 868-869.
5. Inglesby, T. V., T. O'Toole, D. A. Henderson, J. G. Barlett, M. S. Ascher, E. Eitzen, A. M. Friedlander, J. Gerberding, J. Hauer, J. Hughes, et al. 2002. Anthrax as a biological weapon, 2002: updated recommendations for management. J. Am. Med. Assoc. 287: 2236-2252.
6. Marshall, J. D., Jr., P. J. Bartelloni, D. C. Cavanaugh, P. J. Kadull, and K. F. Meyer. 1974. Plague immunization. II. Relation of adverse clinical reactions to multiple immunizations with killed vaccine. J. Infect. Dis. 129(Suppl.): S19-S25.
7. Inglesby, T. V., D. T. Dennis, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A., D. Fine, A. M. Friedlander, J. Hauer, J. F. Koerner, et al. 2000. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. J. Am. Med. Assoc. 283: 2281-2290.
8. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392: 245-252.
9. Steinman, R. M., and M. C. Nussenzweig. 2002. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc. Natl. Acad. Sci. USA 99: 351-358.
10. Hart, D. N. 1997. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90: 3245-3287.
11. Kalinski, P., C. M. Hilkens, E. A. Wierenga, and M. L. Kapsenberg. 1999. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol. Today 20: 561-567.
12. Mellman, I., and R. M. Steinman. 2001. Dendritic cells: specialized and regulated antigen processing machines. Cell 106: 255-258.
13. Banchereau, J., F. Briere, C. Caux, J. Davoust, S. Lebecque, Y. J. Liu, B. Pulendran, and K. Palucka. 2000. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18: 767-811.
14. Liu, Y. J. 2001. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 106: 259-262.
15. Skowera, A., M. Hotopf, E. Sawicka, R. Varela-Calvino, C. Unwin, V. Nikolaou, L. Hull, K. Ismail, A. S. David, S. C. Wessely, and M. Peakman. 2004. Cellular immune activation in gulf war veterans. J. Clin. Immunol. 24: 66-73.
16. Hotopf, M., A. David, L. Hull, K. Ismail, C. Unwin, and S. Wessely. 2000. Role of vaccinations as risk factors for ill health in veterans of the Gulf War: cross sectional study. Br. Med. J. 320: 1363-1367.
17. Arif, S., T. I. Tree, T. P. Astill, J. M. Tremble, A. J. Bishop, C. M. Dayan, B. O. Roep, and M. Peakman. 2004. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J. Clin. Invest. 113: 451-463.
18. Schloot, N. C., G. Meierhoff, M. Karlsson Faresjo, P. Ott, A. Putnam, P. Lehmann, P. Gottlieb, B. O. Roep, M. Peakman, and T. Tree. 2003. Comparison of cytokine ELISpot assay formats for the detection of islet antigen autoreactive T cells: Report of the Third Immunology of Diabetes Society T-Cell Workshop. J. Autoimmun. 21: 365-376.
19. Agrawal, A., J. Lingappa, S. H. Leppla, S. Agrawal, A. Jabbar, C. Quinn, and B. Pulendran. 2003. Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin. Nature 424: 329-334.
20. Leppla, S. H. 1982. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc. Natl. Acad. Sci. USA 79: 3162-3166.
21. O'Brien, J., A. Friedlander, T. Dreier, J. Ezzell, and S. Leppla. 1985. Effects of anthrax toxin components on human neutrophils. Infect. Immun. 47: 306-310.
22. Hoover, D. L., A. M. Friedlander, L. C. Rogers, I. K. Yoon, R. L. Warren, and A. S. Cross. 1994. Anthrax edema toxin differentially regulates lipopolysaccharide-induced monocyte production of tumor necrosis factor α and interleukin-6 by increasing intracellular cyclic AMP. Infect. Immun. 62: 4432-4439.
23. Snijdewint, F. G., P. Kalinski, E. A. Wierenga, J. D. Bos, and M. L. Kapsenberg. 1993. Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J. Immunol. 150: 5321-5329.
24. Xu-Amano, J., H. Kiyono, R. J. Jackson, H. F. Staats, K. Fujihashi, P. D. Burrows, C. O. Elson, S. Pillai, and J. R. McGhee. 1993. Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J. Exp. Med. 178: 1309-1320.
25. van der Pouw Kraan, T. C., A. Snijders, L. C. Boeije, E. R. de Groot, A. E. Alewijnse, R. Leurs, and L. A. Aarden. 1998. Histamine inhibits the production of interleukin-12 through interaction with H2 receptors. J. Clin. Invest. 102: 1866-1873.
26. Rodriguez, V., M. Centeno, and M. Ulrich. 1996. The IgG isotypes of specific antibodies in patients with American cutaneous leishmaniasis; relationship to the cell-mediated immune response. Parasite Immunol. 18: 341-345.
27. Sun, H., K. G. Pollock, and J. M. Brewer. 2003. Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro. Vaccine 21: 849-855.
28. Flynn, S., K. M. Toellner, C. Raykundalia, M. Goodall, and P. Lane. 1998. CD4 T cell cytokine differentiation: the B cell activation molecule. OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1. J. Exp. Med. 188: 297-304.
29. de Jong, E. C., P. L. Vieira, P. Kalinski, J. H. Schuitemaker, Y. Tanaka, E. A. Wierenga, M. Yazdanbakhsh, and M. L. Kapsenberg. 2002. Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse th cell-polarizing signals. J. Immunol. 168: 1704-1709.
30. Cella, M., D. Scheidegger, K. Palmer-Lehmann, P. Lane, A. Lanzavecchia, and G. Alber. 1996. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184: 747-752.